MedTrace Logo

Spermidine Anti-Hypertension Study

NCT04405388 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-01-10

No results posted yet for this study

Summary

The impact of daily spermidine application on arterial blood pressure and other secondary parameters will be evaluated in a double-blind single center 46 patients cross-over study.

Conditions

Interventions

DRUG

Placebo

Placebo will be given orally as capsule (same size and weight as Spermidine capula)

DRUG

Spermidine

Spermidine will be given orally as capsule (4mg/day)

Sponsors & Collaborators

  • University of Graz

    collaborator OTHER

  • ETH Zurich

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital Tuebingen

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Dirk von Lewinski, MD · MUG

  • Simon Sedej, PhD · Medical University of Graz

  • Tobias Eisenberg, PhD · University of Graz

  • Mahmoud Abdellatif, MD, PhD · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2024-11-15
Completion
2024-11-15

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405388 on ClinicalTrials.gov